Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
ETFs with ACAD as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|0%||BioShares Biotechnology Clinical Trials Fund (BBC)||+8.29 (29.40%)|
Company Description (as filed with the SEC)
We are a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders. Led by our novel drug candidate NUPLAZID(TM) (pimavanserin) for the treatment of Parkinson's disease psychosis, we have a portfolio of product opportunities including the following: * Parkinson's disease psychosis (PDP). We have reported positive Phase III pivotal trial results in PDP and believe NUPLAZID has the potential to be the first drug approved in the United States for this disorder. We are currently completing a New Drug Application, or NDA, for NUPLAZID for the treatment of PDP and related preparations to support a review of the NDA by the U.S. Food and Drug Administration, or FDA. We plan to submit the NDA to the FDA in the first quarter of 2015. ... More ...
Where does ACAD fit in the risk graph?
|Annual EPS Est:||$-0.95|
|Quarterly EPS Est:||-0.3|